JOP20230265A1 - تركيبات جسم مضاد ضد tslp واستخداماتها - Google Patents

تركيبات جسم مضاد ضد tslp واستخداماتها

Info

Publication number
JOP20230265A1
JOP20230265A1 JOJO/P/2023/0265A JOP20230265A JOP20230265A1 JO P20230265 A1 JOP20230265 A1 JO P20230265A1 JO P20230265 A JOP20230265 A JO P20230265A JO P20230265 A1 JOP20230265 A1 JO P20230265A1
Authority
JO
Jordan
Prior art keywords
antibody formulations
formulations against
against tslp
tslp
antibody
Prior art date
Application number
JOJO/P/2023/0265A
Other languages
English (en)
Inventor
Kristin Abrams
Alla Polozova
Hao Zhang
Marisa Joubert
Dong Xiang
Kelly Fitzpatrick
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20230265A1 publication Critical patent/JOP20230265A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يتعلق الطلب الحالي، بشكل عام، بتركيبات تشتمل على جسم مضاد ضد TSLP تيزيبيلوماب ومشتقات منه ذات سمات جودة الجسم المضاد.--
JOJO/P/2023/0265A 2021-04-23 2023-10-22 تركيبات جسم مضاد ضد tslp واستخداماتها JOP20230265A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163178938P 2021-04-23 2021-04-23
PCT/US2022/025994 WO2022226339A1 (en) 2021-04-23 2022-04-22 Anti-tslp antibody compositions and uses thereof

Publications (1)

Publication Number Publication Date
JOP20230265A1 true JOP20230265A1 (ar) 2023-10-22

Family

ID=81597810

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0265A JOP20230265A1 (ar) 2021-04-23 2023-10-22 تركيبات جسم مضاد ضد tslp واستخداماتها

Country Status (19)

Country Link
US (1) US20240190951A1 (ar)
EP (1) EP4326766A1 (ar)
JP (1) JP2024517418A (ar)
KR (1) KR20240000537A (ar)
CN (1) CN117203233A (ar)
AR (1) AR125408A1 (ar)
AU (1) AU2022262421A1 (ar)
BR (1) BR112023021867A2 (ar)
CA (1) CA3216655A1 (ar)
CL (1) CL2023003155A1 (ar)
CO (1) CO2023014181A2 (ar)
CR (1) CR20230531A (ar)
IL (1) IL307540A (ar)
JO (1) JOP20230265A1 (ar)
MX (1) MX2023012363A (ar)
PE (1) PE20240068A1 (ar)
TW (1) TW202308690A (ar)
UY (1) UY39736A (ar)
WO (1) WO2022226339A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
IL324470A (en) 2023-05-18 2026-01-01 Medimmune Llc Treatment of corticosteroid-dependent asthma using anti-TSLP antibody
WO2025147632A1 (en) 2024-01-05 2025-07-10 Medimmune, Llc Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
CN102281901A (zh) * 2008-11-20 2011-12-14 弗·哈夫曼-拉罗切有限公司 治疗性蛋白质制剂
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
WO2015116315A1 (en) 2014-01-29 2015-08-06 Amgen Inc. Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
FI3218005T3 (fi) * 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
ES2978396T3 (es) * 2017-08-01 2024-09-11 Amgen Inc Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
TW202541859A (zh) 2018-10-15 2025-11-01 美商安進公司 具有阻尼機構之藥物遞送裝置及自動注射器
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
JP7562563B2 (ja) 2019-04-30 2024-10-07 アムジエン・インコーポレーテツド バイオ医薬品生産における細胞株選択のためのデータ駆動予測モデリング
AU2020288652A1 (en) 2019-06-05 2021-11-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins

Also Published As

Publication number Publication date
TW202308690A (zh) 2023-03-01
JP2024517418A (ja) 2024-04-22
KR20240000537A (ko) 2024-01-02
PE20240068A1 (es) 2024-01-11
CR20230531A (es) 2024-01-08
AR125408A1 (es) 2023-07-12
MX2023012363A (es) 2023-11-01
CO2023014181A2 (es) 2023-10-30
EP4326766A1 (en) 2024-02-28
CL2023003155A1 (es) 2024-04-19
CN117203233A (zh) 2023-12-08
BR112023021867A2 (pt) 2023-12-19
WO2022226339A9 (en) 2023-08-24
CA3216655A1 (en) 2022-10-27
UY39736A (es) 2022-10-31
WO2022226339A1 (en) 2022-10-27
US20240190951A1 (en) 2024-06-13
IL307540A (en) 2023-12-01
AU2022262421A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
JOP20230265A1 (ar) تركيبات جسم مضاد ضد tslp واستخداماتها
EP4524148A3 (en) Anti-vegf protein compositions and methods for producing the same
MX2020008772A (es) Conjugados de il-15, y sus usos.
MX2025005441A (es) Composiciones de inoculantes microbianos y metodos relacionados
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
MX2020013421A (es) Composiciones de dióxido de silicio de carbono poroso biogénico, métodos de elaboracion y uso de estas.
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
AU2016320806A8 (en) Stable inoculant compositions and methods for producing same
UY37055A (es) Composiciones inoculantes estables y métodos para su producción
AR111835A1 (es) Composiciones estables de inoculantes que comprenden aceites vegetales metilados
MX2020001413A (es) Composiciones de inoculantes microbianos y metodos relacionados.
PH12021551100A1 (en) Dried biological compositions and methods thereof
CR20200342A (es) Composiciones de edb que se dirigen a il-12
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
WO2022226342A3 (en) Modified anti-tslp antibodies
JOP20230239A1 (ar) أجسام مضادة للنكتين-4 واستخدامتها
MX2022015801A (es) Sistemas de expresion de baculovirus.
EP4389209A3 (en) Fecal microbiota composition, for use in reducing treatment-induced inflammation
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
MX2025007537A (es) Composiciones de peptido estables
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
SA523450167B1 (ar) أجسام مضادة لعامل التحول الوسيطي الظهاري واستخداماتها
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
TWD206657S (zh) 喇叭